WO2012018761A3 - Method of treatment of androgen-mediated cancers - Google Patents

Method of treatment of androgen-mediated cancers Download PDF

Info

Publication number
WO2012018761A3
WO2012018761A3 PCT/US2011/046193 US2011046193W WO2012018761A3 WO 2012018761 A3 WO2012018761 A3 WO 2012018761A3 US 2011046193 W US2011046193 W US 2011046193W WO 2012018761 A3 WO2012018761 A3 WO 2012018761A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen
treatment
mediated cancers
mediated
methods
Prior art date
Application number
PCT/US2011/046193
Other languages
French (fr)
Other versions
WO2012018761A2 (en
Inventor
Barry Scott Brand
Daniel Joesph Burch
Ranga Krishnan
Original Assignee
Cenerx Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenerx Biopharma, Inc. filed Critical Cenerx Biopharma, Inc.
Publication of WO2012018761A2 publication Critical patent/WO2012018761A2/en
Publication of WO2012018761A3 publication Critical patent/WO2012018761A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are methods for treating androgen-mediated carcinomas. The methods include administering a therapeutically effective amount of a pharmaceutical product that includes at least one selective and reversible monoamine oxidase A inhibitor.
PCT/US2011/046193 2010-08-05 2011-08-02 Method of treatment of androgen-mediated cancers WO2012018761A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37094210P 2010-08-05 2010-08-05
US61/370,942 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012018761A2 WO2012018761A2 (en) 2012-02-09
WO2012018761A3 true WO2012018761A3 (en) 2012-05-24

Family

ID=45560015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046193 WO2012018761A2 (en) 2010-08-05 2011-08-02 Method of treatment of androgen-mediated cancers

Country Status (1)

Country Link
WO (1) WO2012018761A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
US9675620B2 (en) 2011-07-26 2017-06-13 University Of Southern California MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
EP2736506B1 (en) * 2011-07-26 2018-09-05 University Of Southern California Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
CN103040836A (en) * 2013-01-11 2013-04-17 吴伯阳 Use of moclobemide in prostatic cancer resistance and pharmaceutical preparation of moclobemide
CN110462401B (en) * 2017-01-23 2023-01-17 古斯塔夫·鲁西研究所 Use of enhancers of cellular autophagy for sensitizing tumors to radiotherapy
CA3097739A1 (en) * 2018-01-23 2019-08-01 Institut Gustave-Roussy Use of minaprine to reduce tumor growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176469A1 (en) * 2000-07-27 2004-09-09 Thomas Nadackal Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176469A1 (en) * 2000-07-27 2004-09-09 Thomas Nadackal Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONGJUAN ZHAO ET AL.: "Inhibition of monoamine oxidase A promotes secretory differentiation is basal prostatic epithelial cells.", DIFFERENTIATION., vol. 76, no. 7, September 2008 (2008-09-01), pages 820 - 830, XP026772234, DOI: doi:10.1111/j.1432-0436.2007.00263.x *
LAWRENCE TRUE ET AL.: "A molecular correlate to the Gleason grading system f or prostate adenocarcinoma.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITIED STATES OF AMERICA, vol. 103, no. 29, 18 July 2006 (2006-07-18), pages 10991 - 10996 *
VINCENT FLAMAND ET AL.: "Targeting monoamine oxidase A in advanced prostate cancer.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY., vol. 136, no. 11, 4 March 2010 (2010-03-04), pages 1761 - 1771, XP019849130 *

Also Published As

Publication number Publication date
WO2012018761A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
EP4279087A3 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2012103059A3 (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
MX2010006823A (en) Methods for the treatment of gout.
SG10201903119QA (en) Polypeptide vaccine
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
BRPI0917444A2 (en) gastric retention pharmaceutical compositions for the treatment and prevention of snc diseases
WO2012018761A3 (en) Method of treatment of androgen-mediated cancers
EP2165715A4 (en) Therapeutic agent for cancer, and method for treatment of cancer
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
BRPI0816255A2 (en) Pharmaceutical product, use of the product, method for the prophylaxis or treatment of diseases, and pharmaceutically acceptable composition.
EP2012807A4 (en) Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
WO2010091384A3 (en) Cadherin-11 inhibitors and methods of use thereof
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011009039A3 (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
WO2012040082A3 (en) Antidiabetic solid pharmaceutical compositions
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
EP3677267A4 (en) Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
WO2012018759A3 (en) Method of treatment of androgen-mediated cancers
WO2016126572A3 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP4013485A4 (en) Methods and devices for transdermal neurostimulation treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815154

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815154

Country of ref document: EP

Kind code of ref document: A2